Microscopic yeast have been wreaking havoc in hospitals around the world—creeping into catheters, ventilator tubes, and IV lines—and causing deadly invasive infection. One culprit species, Candida auris, is resistant to many antifungals, meaning once a person is infected, there are limited treatment options. But in a recent Antimicrobial Agents and Chemotherapy study, researchers confirmed a new drug compound kills drug-resistant C. auris, both in the laboratory and in a mouse model that mimics human infection.
APX001, the prodrug of the active moiety APX001A, is currently in clinical development by Amplyx Pharmaceuticals. It works through a novel mechanism of action. Unlike other antifungal agents that poke holes in yeast cell membranes or inhibit sterol synthesis, the new drug targets an enzyme called Gwt1, which is required for anchoring critical proteins to the fungal cell wall. This means C. auris can’t grow properly and has a harder time forming drug-resistant fungal biofilms that are a stubborn source of hospital outbreaks. Gwt1 is highly conserved across fungal species, suggesting the new drug could treat a broad range of fungal infections.
“The drug is first in a new class of antifungals, which could help stave off drug resistance. Even the most troublesome strains are unlikely to have developed workarounds for its mechanism of action,” said study lead Mahmoud A. Ghannoum, PhD, professor of dermatology at Case Western Reserve University School of Medicine and director of the Center for Medical Mycology at Case Western Reserve University and University Hospitals Cleveland Medical Center.
In the new study, Ghannoum’s team tested the drug against 16 different C. auris strains, collected from infected patients in Germany, Japan, South Korea, and India. When they exposed the isolates to the new drug, they found it more potent than nine other currently available antifungals. According to the authors, the concentration of study drug needed to kill C. auris growing in laboratory dishes was “eight-fold lower than the next most active drug, anidulafungin, and more than 30-fold lower than all other compounds tested.”
The researchers also developed a new mouse model of invasive C. auris infection for the study. Said Ghannoum, “To help the discovery of effective drugs it will be necessary to have an animal model that mimics this infection. Our work helps this process in two ways: first we developed the needed animal model that mimics the infection caused by this devastating yeast, and second, we used the developed model to show the drug is effective in treating this infection.”
Ghannoum studied immunocompromised mice infected with C. auris via their tail vein—similar to very sick humans in hospitals who experience bloodstream infections. Infected mice treated with APX001 and anidulafungin had significant reductions in kidney and lung fungal burden two days post-treatment, compared to control animals. APX001 also significantly decreased fungal burden in the brain, consistent with brain penetration, whereas reduction with anidulafungin did not reach significance. The results suggest the new drug could help treat even the most invasive infections.
According to Ghannoum, the most exciting element of the study is that it brings a promising antifungal one step closer to patients. It helps lay the foundation for phase 2 clinical trials that study that study the safety and efficacy of new drugs in patients with fungal infections. There is an urgent need for such studies, as C. auris infection has become a serious threat to healthcare facilities worldwide—and resistance to commercially available antifungal drugs is rising.
“Limited treatment options calls for the development of new drugs that are effective against this devastating infection,” Ghannoum said. “We hope that we contributed in some way towards the development of new drugs.”
The Latest on: Antifungal
via Google News
The Latest on: Antifungal
- How a Chicago Woman Fell Victim to Candida Auris, a Drug-Resistant Fungus on April 17, 2019 at 10:21 am
C. auris, a germ that typically is resistant to major antifungal medications, has been quietly confounding doctors, hospitals and infectious disease scientists around the world. First identified in ... […]
- Cypress Oil: What You Need to Know on April 17, 2019 at 7:35 am
The majority of studies focus on essential oil made from this particular tree. Cypress oil has many health benefits, as it has antibacterial, antimicrobial, and antifungal properties. According to a ... […]
- New superbug Candida auris is not in central Illinois — yet on April 16, 2019 at 5:43 pm
Candida auris, a new strain of yeast, can cause serious infections and is resistant to antifungal medications and many disinfection methods. According to the Centers for Disease Control and Prevention ... […]
- Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019 on April 16, 2019 at 5:00 am
Overall, the rezafungin presentations at ECCMID demonstrate the novel agent’s potent antifungal activity and distinct pharmacokinetic and pharmacodynamic profile that together provide for prolonged ... […]
- DEADLY SECRECY: Hospitals and nursing homes quietly battle a hardy fungus on April 16, 2019 at 2:03 am
C. auris is so tenacious, in part, because it is impervious to major antifungal medications, making it a new example of one of the world’s most intractable health threats: the rise of drug-resistant ... […]
- Antifungal Drugs Market Size Driving Factors, Industry Growth, Key Vendors and Forecasts to 2024 on April 15, 2019 at 10:18 am
Apr 15, 2019 (Heraldkeeper via COMTEX) -- This detailed report on 'Antifungal Drugs Market' put together by Market Study Report, LLC, offers a succinct study on regional forecast, industry size, ... […]
- As Drug Resistance Grows, Amplyx Tests New Antifungal Drug on April 15, 2019 at 9:52 am
While fungal infections may seem like an annoyance rather than a serious health problem, sick people in hospitals and long-term care facilities are contracting potentially deadly infections that ... […]
- Global Anti-infective Agents (Antibacterial, Antifungal, Antiviral) Market Forecasts to 2026 - ResearchAndMarkets.com on April 11, 2019 at 10:01 pm
DUBLIN--(BUSINESS WIRE)--The "Anti-infective Agents Market Size, Share & Trend Analysis By Type (Antibacterial, Antifungal, Antiviral), By Route of Administration (Oral, Topical, IV), By ... […]
- Antifungal Drugs Market Current Trends And Future Demand 2027 Merck & Co, Novartis AG, Sanofi Pfizer, Inc, Bayer AG on April 10, 2019 at 7:21 am
Antifungal Drugs market is anticipated to grow in the forecast period owing to driving factors such as increasing incidence of fungal infection, rising awareness levels pertaining to myriad fungal ... […]
via Bing News